Titre:
  • Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
Auteur:Schuster, Michael; Zijlstra, Josée J.M.; Casasnovas, René Olivier; Vermaat, Joost J.S.P.; Kalakonda, Nagesh; Goy, Andre; Choquet, Sylvain; Neste, Eric Van Den; Hill, Brian; Thieblemont, Catherine; Cavallo, Federica; De la Cruz, Fátima; Kuruvilla, John; Hamad, Nada; Jäger, Ulrich; Caimi, Paolo; Gurion, Ronit; Warzocha, Krzysztof; Bakhshi, Sameer; Sancho, Juan Manuel; Follows, George; Egyed, Miklos; Offner, Fritz; Vassilakopoulos, Theodoros; Samal, Priyanka; Ku, Matthew; Ma, Xiwen; Corona, Kelly; Chamoun, Kamal; Shah, Jatin; Shacham, Sharon; Kauffman, Michael; Canales, Miguel; Maerevoet, Marie
Informations sur la publication:Clinical Lymphoma, Myeloma and Leukemia
Statut de publication:Publié, 2022
Sujet CREF:Cancérologie
Information et communication
Mots-clés:Exportin-1
Monotherapy
Pretreated
Refractory
Relapsed
SINE compounds
XPO1
Note générale:SCOPUS: ar.j
DecretOANoAutActif
Langue:Anglais
Identificateurs:urn:issn:2152-2650
info:doi/10.1016/j.clml.2021.12.016
info:pii/S2152265021024800
info:scp/85123387099